Seasoned investor and operational executive focused on healthcare and growth-stage technology companies, Margaret Nickens brings public markets and private equity sensibilities to board and portfolio roles. She has led cross-functional teams, structured transactions and overseen M&A and capital-raising initiatives at mid-market firms. Known for strategic diligence, commercial scaling and governance expertise, she advises CEOs and investors on go-to-market, partnerships and exit planning.
Seasoned investor and operational executive focused on healthcare and growth-stage technology companies, Margaret Nickens brings public markets and private equity sensibilities to board and portfolio roles. She has led cross-functional teams, structured transactions and overseen M&A and capital-raising initiatives at mid-market firms. Known for strategic diligence, commercial scaling and governance expertise, she advises CEOs and investors on go-to-market, partnerships and exit planning.
Combines public-market rigor with private-equity playbooks to back growth-stage healthcare and technology companies where commercial strategy and governance drive value. Prioritizes diligence on product-market fit, revenue model scalability and partnership-led distribution; structures deals that align management incentives with clear milestones and exit optionality. Employs a pragmatic time horizon focused on accelerated commercial scaling and de-risking via staged capital, active board engagement, and disciplined M&A or capital-raise pathways to crystallize returns.
Combines public-market rigor with private-equity playbooks to back growth-stage healthcare and technology companies where commercial strategy and governance drive value. Prioritizes diligence on product-market fit, revenue model scalability and partnership-led distribution; structures deals that align management incentives with clear milestones and exit optionality. Employs a pragmatic time horizon focused on accelerated commercial scaling and de-risking via staged capital, active board engagement, and disciplined M&A or capital-raise pathways to crystallize returns.
| Trades 629 | Longs Won 426/629 67% | Profit Factor 9.14 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $231,696.69 |
| Average Win $78,499.98 | Best Trade (Jul 15) $3.2M | Sharpe Ratio -1,769.61 |
| Average Loss -$18,025.72 | Worst Trade (Jul 10) -$370,761.56 | Z-Score 5.89 (100%) |
| Commissions $0 | Avg. Trade Length 9m 3w 4d | Expectancy $47,347.81 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 7,463 | 6,716 | 5,970 | 5,224 | 4,478 | 3,731 | 2,985 | 2,239 | 1,493 | 746 |